<DOC>
	<DOC>NCT01269606</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of the trial is to compare pharmacokinetics (at which rate the body eliminates the substance from the body) of insulin aspart with fast-acting insulin human following intravenous (IV) infusion or intramuscular (IM) injection in Japanese subjects with type 1 diabetes mellitus.</brief_summary>
	<brief_title>Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months Treated with multiple daily insulin injections for at least 12 months Current daily basal insulin requirement above or equal to 0.3 U/kg/day Glycosylated haemoglobin A1c (HbA1c) below or equal to 10.0% Body Mass Index (BMI) 18.028.0 kg/m^2 Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to trial start (screening) Surgery or trauma with significant blood loss (more than 500 mL) within 3 months prior to trial start (screening) Subject who smokes more than 10 cigarettes or the equivalent per day Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>